Nephrectomy is considered the backbone of managing patients with localized and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy has been widely investigated with cytokines and targeted therapy, but it is still unclear in the immunotherapy era.
We investigated the Meet-URO-15 study dataset of 571 pretreated mRCC patients receiving nivolumab as second or further lines about the prognostic role of the previous nephrectomy (received in either the localized or metastatic setting) in the overall population and according to the Meet-URO score groups.
Patients who underwent nephrectomy showed a significantly reduced risk of death (HR 0.44, 95% CI 0.32-0.60, p < 0.001) with a longer median overall survival (OS) (35.9 months vs 12.1 months), 1-year OS of 71.6% vs 50.5% and 2-years OS of 56.5% vs 22.0% compared to those who did not. No significant interaction between nephrectomy and the overall five Meet-URO score risk groups was observed (p = 0.17). It was statistically significant when merging group 1 with 2 and 3 and group 4 with 5 (p = 0.038) and associated with a longer OS for the first three prognostic groups (p < 0.001), but not for groups 4 and 5 (p = 0.54).
Our study suggests an overall positive impact of the previous nephrectomy on the outcome of pretreated mRCC patients receiving immunotherapy. The clinical relevance of cytoreductive nephrectomy, optimal timing and patient selection deserves further investigation, especially for patients with Meet-URO scores of 1 to 3, who are the once deriving benefit in our analyses. However, that benefit is not evident for IMDC poor-risk patients (including the Meet-URO score groups 4 and 5) and a subgroup of IMDC intermediate-risk patients defined as group 4 by the Meet-URO score.
Journal of translational medicine. 2022 Sep 30*** epublish ***
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Daniele Santini, Francesco Atzori, Marilena Di Napoli, Orazio Caffo, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Pasquale Rescigno, Sebastiano Buti
Medical Oncology Unit, Ospedale San Paolo, Savona, Italy., Department of Health Sciences, Section of Biostatistics, University of Genova, Genoa, Italy., Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ., Oncology 1 Unit, Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy., Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy., Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy., Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Medical Oncology Unit, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy., Division of Medical Oncology, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy., SS Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Department of Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy., Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genoa, Italy., Department of Medical Oncology, Centro di Riferimento, Oncologico di Aviano CRO-IRCCS, Aviano, Italy., Medical Oncology Unit, Department of Oncology and Hemathology, University Hospital of Modena, Modena, Italy., Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy., Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., U.O. Oncologia, Ospedale di Camposampiero, Camposampiero, Italy., Oncology Unit, Macerata Hospital, Macerata, Italy., Medical Oncology Department, Campus Bio-Medico University of Rome, 00128, Rome, Italy., Department of Medical Oncology, Ospedale Michele e Pietro Ferrero, Verduno, (CN) ASL CN2, Italy., Department of Oncology, Medical Oncology, University Hospital Policlinico-San Marco, Catania, Italy., UOC Oncologia Medica, "Sapienza University", Polo Pontino, Rome, Italy., Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy., Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy., Medical Oncology Department, Santa Chiara Hospital, Trento, Italy., UOC Oncologia Medica, Istituto Fondazione G. Giglio, Cefalù, Italy., Oncology Department, Gemelli Molise, Campobasso, Italy., Department of Oncology and advanced technologies, AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy., Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy., Division of Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy., Oncology Unit, Villa Scassi Hospital, Genoa, Italy., Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Florence, Italy., Medical Oncology Unit, University Hospital of Parma, Parma, Italy.